Treasury expected to be harder on China biotech deals in new rules
The pharma industry is bracing for a more stringent assessment of China deals from the Treasury Department, despite months of work to escape a harsh clampdown on buying new assets there. Endpoints News spoke with ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.